TY - JOUR
T1 - 3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)- one, a novel adenosine receptor antagonist with A2A-mediated neuroprotective effects
AU - Scatena, Alessia
AU - Fornai, Francesco
AU - Trincavelli, Maria Letizia
AU - Taliani, Sabrina
AU - Daniele, Simona
AU - Pugliesi, Isabella
AU - Cosconati, Sandro
AU - Martini, Claudia
AU - Da Settimo, Federico
PY - 2011/6/10
Y1 - 2011/6/10
N2 - In this study, compound FTBI (3-(2-furyl)-10-(2-phenylethyl)[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one) was selected from a small library of triazinobenzimidazole derivatives as a potent A2Aadenosine receptor (AR) antagonist and tested for its neuroprotective effects against two different kinds of dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP+) and methamphetamine (METH), in rat PC12 and in human neuroblastoma SH-SY5Y cell lines. FTBI, in a concentration range corresponding to its affinity for A2AAR subtype, significantly increased the number of viable PC12 cells after their exposure to METHand, to a similar extent, to MPP+, as demonstrated in both trypan blue exclusion assay and in cytological staining. These neuroprotective effects were also observed with a classical A2AAR antagonist, ZM241385, and appeared to be completely counteracted by the AR agonist, NECA, supporting A2AARs are directly involved in FTBI-mediated effects. Similarly, in human SH-SY5Y cells, FTBI was able to prevent cell toxicity induced by MPP+ and METH, showing that this A2AAR antagonist has a neuroprotective effect independently by the specific cell model. Altogether these results demonstrate that the A2AAR blockade mediates cell protection against neurotoxicity induced by dopaminergic neurotoxins in dopamine containing cells, supporting the potential use of A2AAR antagonists in dopaminergic degenerative diseases including Parkinson's disease.
AB - In this study, compound FTBI (3-(2-furyl)-10-(2-phenylethyl)[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one) was selected from a small library of triazinobenzimidazole derivatives as a potent A2Aadenosine receptor (AR) antagonist and tested for its neuroprotective effects against two different kinds of dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP+) and methamphetamine (METH), in rat PC12 and in human neuroblastoma SH-SY5Y cell lines. FTBI, in a concentration range corresponding to its affinity for A2AAR subtype, significantly increased the number of viable PC12 cells after their exposure to METHand, to a similar extent, to MPP+, as demonstrated in both trypan blue exclusion assay and in cytological staining. These neuroprotective effects were also observed with a classical A2AAR antagonist, ZM241385, and appeared to be completely counteracted by the AR agonist, NECA, supporting A2AARs are directly involved in FTBI-mediated effects. Similarly, in human SH-SY5Y cells, FTBI was able to prevent cell toxicity induced by MPP+ and METH, showing that this A2AAR antagonist has a neuroprotective effect independently by the specific cell model. Altogether these results demonstrate that the A2AAR blockade mediates cell protection against neurotoxicity induced by dopaminergic neurotoxins in dopamine containing cells, supporting the potential use of A2AAR antagonists in dopaminergic degenerative diseases including Parkinson's disease.
KW - AAR antagonists
KW - Cell viability
KW - Human neuroblastoma cells
KW - Neuroprotection
KW - Neurotoxins
KW - PC12 cells
UR - http://www.scopus.com/inward/record.url?scp=84876034737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876034737&partnerID=8YFLogxK
U2 - 10.1021/cn200036s
DO - 10.1021/cn200036s
M3 - Article
C2 - 22860174
AN - SCOPUS:84876034737
VL - 2
SP - 526
EP - 535
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
SN - 1948-7193
IS - 9
ER -